Patients in treat-to-target ULT arm had higher five-year survival and lower risk for major adverse cardiovascular events<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Feb. 3, 2026 (HealthDay News) — For patients with gout who were newly prescribed urate-lowering treatment (ULT), achieving serum urate levels lower than 6 mg\/dL is associated with a lower risk for major adverse cardiovascular events, according to a study published online Jan. 26 in JAMA Internal Medicine<\/em>.<\/p>\n Edoardo Cipolletta, Ph.D., from the University of Nottingham in the United Kingdom, and colleagues examined the association between achieving a serum urate treatment target lower than 6 mg\/dL and cardiovascular events among patients with gout who were newly prescribed ULT. Patients were assigned to the treat-to-target (T2T) ULT arm or the non-T2T ULT arm if they achieved or did not achieve a serum urate level lower than 6 mg\/dL, respectively, within 12 months of their first ULT prescription receipt.<\/p>\n The researchers found that 27.3 percent of the 109,504 patients were included in the T2T ULT arm. Compared with those in the non-T2T ULT arm, patients in the T2T ULT arm had higher five-year survival (weighted survival difference, 1.0 percent) and a lower risk for major adverse cardiovascular events (weighted hazard ratio, 0.91). Compared with those with moderate risk, there was a greater association for people at high and very high cardiovascular risk. A larger risk reduction was seen for patients who achieved a lower serum urate target of less than 5 mg\/dL (weighted survival difference, 2.6 percent; weighted hazard ratio, 0.77).<\/p>\n “Previous research from Nottingham showed treat-to-target urate-lowering treatment prevents gout flares,” lead author Abhishek Abhishek, Ph.D., also from the University of Nottingham, said in a statement. “This current study provides an added benefit of reduced risk of heart attack, stroke, and death due to these diseases.”<\/p>\n Several authors disclosed ties to the information technology and biopharmaceutical industries.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n